Bumetanide to Torsemide Dose Equivalence
Bumex (bumetanide) 1 mg is approximately equivalent to 10-20 mg of torsemide.
Dose Conversion Rationale
The FDA-approved drug label for Bumex establishes that 1 mg bumetanide has diuretic potency equivalent to approximately 40 mg furosemide 1. Using the well-established furosemide-to-torsemide conversion ratio, this translates to a bumetanide-to-torsemide ratio of approximately 1:10 to 1:20.
Supporting Evidence from Guidelines
Multiple authoritative guidelines consistently demonstrate this conversion:
The 2019 ACC Expert Consensus 2 shows bumetanide usual outpatient dosing of 0.5-2 mg once to twice daily (maximum 10 mg/day), while torsemide dosing is 10-40 mg once daily (maximum 200 mg/day)
The 2013 ACCF/AHA Heart Failure Guidelines 3, 4 list bumetanide initial doses of 0.5-1.0 mg with maximum 10 mg daily, compared to torsemide 10-20 mg initially with maximum 200 mg daily
The 2016 ESC Guidelines 5 present similar dosing: bumetanide 0.5-1.0 mg initially (1-5 mg usual daily dose) versus torsemide 5-10 mg initially (10-20 mg usual daily dose)
Clinical Application
For practical conversion: Start with 1 mg bumetanide = 10 mg torsemide as the conservative baseline ratio. This aligns with the FDA label stating bumetanide can be substituted at approximately a 1:40 ratio to furosemide 1, and the standard 40 mg furosemide = 10 mg torsemide equivalence.
Important Caveats
Bioavailability differences matter: Torsemide has superior oral bioavailability (80-90%) compared to furosemide (10-90%), but bumetanide also has good oral bioavailability with near 1:1 oral-to-IV equivalence 6
Recent mechanistic data 7 from the TRANSFORM-Mechanism trial found that a 4:1 furosemide-to-torsemide ratio resulted in similar natriuresis, suggesting the traditional 40:10 conversion may overestimate torsemide potency. This would translate to approximately 1 mg bumetanide = 10 mg torsemide
Monitor response closely: The 2008 ESC Guidelines 8 note that 0.5-1 mg bumetanide equals 10-20 mg torsemide at admission for acute heart failure, emphasizing the need for frequent assessment of urine output and clinical response
Monitoring Requirements
When converting between these agents:
- Assess daily weights, urine output, and volume status
- Monitor electrolytes (particularly potassium and magnesium) at least daily initially
- Check renal function (creatinine, BUN)
- Adjust doses every 2-3 days based on clinical response 2, 6
Bottom line: Use a 1:10 conversion ratio (1 mg bumetanide = 10 mg torsemide) as your starting point, then titrate based on diuretic response and clinical status.